[go: up one dir, main page]

WO2001060412A3 - Modification of biopolymers for improved drug delivery - Google Patents

Modification of biopolymers for improved drug delivery Download PDF

Info

Publication number
WO2001060412A3
WO2001060412A3 PCT/US2001/004925 US0104925W WO0160412A3 WO 2001060412 A3 WO2001060412 A3 WO 2001060412A3 US 0104925 W US0104925 W US 0104925W WO 0160412 A3 WO0160412 A3 WO 0160412A3
Authority
WO
WIPO (PCT)
Prior art keywords
biopolymers
modification
drug delivery
improved drug
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004925
Other languages
French (fr)
Other versions
WO2001060412A2 (en
Inventor
Pericles Calias
Robert J Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CA002400205A priority Critical patent/CA2400205A1/en
Priority to EP01910775A priority patent/EP1263472A2/en
Priority to AU2001238346A priority patent/AU2001238346A1/en
Priority to IL15102401A priority patent/IL151024A0/en
Priority to JP2001559507A priority patent/JP2003522806A/en
Publication of WO2001060412A2 publication Critical patent/WO2001060412A2/en
Publication of WO2001060412A3 publication Critical patent/WO2001060412A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.
PCT/US2001/004925 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery Ceased WO2001060412A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002400205A CA2400205A1 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery
EP01910775A EP1263472A2 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery
AU2001238346A AU2001238346A1 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery
IL15102401A IL151024A0 (en) 2000-02-15 2001-02-15 Conjugates of a biopolymer and a therapeutic agent
JP2001559507A JP2003522806A (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US60/182,558 2000-02-15
US21150800P 2000-06-14 2000-06-14
US60/211,508 2000-06-14

Publications (2)

Publication Number Publication Date
WO2001060412A2 WO2001060412A2 (en) 2001-08-23
WO2001060412A3 true WO2001060412A3 (en) 2002-01-24

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004925 Ceased WO2001060412A2 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Country Status (6)

Country Link
EP (1) EP1263472A2 (en)
JP (1) JP2003522806A (en)
AU (1) AU2001238346A1 (en)
CA (1) CA2400205A1 (en)
IL (1) IL151024A0 (en)
WO (1) WO2001060412A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440684A (en) * 2018-03-22 2018-08-24 华侨大学 A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP2004525621A (en) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Bifunctional fusion protein having glucocerebrosidase activity
WO2004060404A1 (en) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Drug carrier
US7803386B2 (en) 2003-06-05 2010-09-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2004110339A2 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
AU2004281694B2 (en) * 2003-10-10 2012-05-03 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
WO2006028110A1 (en) 2004-09-07 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
US7341720B2 (en) 2005-04-06 2008-03-11 Genzyme Corporation Targeting of glycoprotein therapeutics
WO2007008904A2 (en) 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
CN102978185B (en) 2007-01-18 2015-02-11 建新公司 Oligosaccharides comprising an aminooxy group and conjugates thereof
MX364498B (en) 2008-12-16 2019-04-29 Genzyme Corp Oligosaccharide-protein conjugates.
HUE033169T2 (en) 2011-03-03 2017-11-28 Chugai Pharmaceutical Co Ltd Derivative of hyaluronic acid modified with amino-carboxylic acid
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
WO2014038641A1 (en) 2012-09-05 2014-03-13 中外製薬株式会社 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
KR102049568B1 (en) * 2013-04-01 2019-11-27 삼성전자주식회사 Composition for nucleic acid delivery containing hyaluronic acid
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
WO1993008842A1 (en) * 1991-11-08 1993-05-13 Somatogen, Inc. Hemoglobins as drug delivery agents
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
WO1999066063A2 (en) * 1998-06-16 1999-12-23 Isis Pharmaceuticals, Inc. Nucleosidic and non-nucleosidic folate conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
DE69433723T3 (en) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
WO1993008842A1 (en) * 1991-11-08 1993-05-13 Somatogen, Inc. Hemoglobins as drug delivery agents
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
WO1999066063A2 (en) * 1998-06-16 1999-12-23 Isis Pharmaceuticals, Inc. Nucleosidic and non-nucleosidic folate conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DADLEY-MOORE D L ET AL: "Synthetic peptide antigens induce antibodies to Taenia ovis oncospheres", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 11-12, March 1999 (1999-03-01), pages 1506 - 1515, XP004158279, ISSN: 0264-410X *
GEORGE Y. WU AND CATHERINE H. WU: "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 10, 5 April 1987 (1987-04-05), pages 4429 - 4432, XP002176177 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440684A (en) * 2018-03-22 2018-08-24 华侨大学 A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application

Also Published As

Publication number Publication date
EP1263472A2 (en) 2002-12-11
AU2001238346A1 (en) 2001-08-27
JP2003522806A (en) 2003-07-29
CA2400205A1 (en) 2001-08-23
WO2001060412A2 (en) 2001-08-23
IL151024A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
NO20015584L (en) Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment
ES2173641T3 (en) COMPOSITION OF OPIACE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES.
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2006014673A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
ATE349438T1 (en) CYTOTOXIC ACTIVE INGREDIENTS CONTAINING TAXANES AND THEIR THERAPEUTIC USE
WO2003061577A3 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
WO2007113687A3 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
ATE432689T1 (en) SUSTAINED RELEASE DRUG FORMULATIONS CONTAINING A CARRIER PEPTIDE
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU1079701A (en) Oral transmucosal drug dosage using solid solution
ATE344801T1 (en) CYTOTOXIC AGENTS CONTAINING DOXORUBICIN AND DAUNORUBICIN AND THEIR THERAPEUTIC USE
GEP20022804B (en) Erythropoietin Derivatives
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
TR200200710T2 (en) Pharmaceutical liquid compositions produced to prevent the unpleasant taste of the drug.
TW200514590A (en) Hydrophilic adhesives for delivery of herbal medicines
WO2006130455A3 (en) Bioresorbable polymer matrices and methods of making and using the same
MXPA02012075A (en) Composition for pain mediation and apparatus and method of use thereof.
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
DE60111637D1 (en) BIOMATERIAL IN THE FORM OF MICROPARTICLES OF HYALURONIC SUCTION FOR MEDICAL USE
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TW200635616A (en) Organic compounds
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
BE2016C017I2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 151024

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2400205

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 559507

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001910775

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910775

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642